Biotech Funding Terms Glossary: VC, IPO & M&A Definitions (2026)

Core VC money math

Pre-money valuation: Company value before new money comes in. Used to calculate price per share and dilution.
Post-money valuation: Pre-money + new money invested. If you raise $50M on a $200M pre, post is $250M.
Dilution: The percentage ownership existing shareholders give up when new shares are issued. It's not "bad" — it's the cost of capital.
Option pool / ESOP: Shares reserved for employees. Investors often require a "pool top-up" at a new round, which increases dilution to existing holders.
Price per share: Implied share price set by the financing. Determines how many new shares are issued for the amount raised.
Fully diluted (FD) shares: Total shares assuming all options, warrants, and convertibles are exercised or converted. "FD % ownership" is what most investors care about.
Runway: How long the company can operate at current burn rate before running out of cash — often stated in months.
Burn rate: Net cash spent per month or quarter. In biotech, clinical trials and manufacturing scale-up usually drive burn.

Round types in biotech

Seed: Early capital to form the company and generate initial data — target validation, lead discovery, IND planning.
Series A / B / C: Staged VC rounds. In biotech: A often funds IND + Phase 1; B funds Phase 1/2; C funds Phase 2/3 or multiple programs. These are general rules, not hard conventions.
Extension / "A-1", "B-2", etc.: An add-on to an existing round, sometimes at the same price, sometimes at a step-up.
Bridge round: Short-term financing meant to reach a specific milestone (e.g., data readout) or an IPO/M&A process.
Crossover round: Private round that includes public-market investors, typically ahead of an IPO. Signals IPO intent and helps anchor valuation.
Venture debt: Debt financing for VC-backed companies, often with warrants. Extends runway but adds repayment obligations.

Term sheet mechanics

Preferred vs common stock: Preferred (investors) usually carries extra rights — liquidation preference, anti-dilution, voting. Common (founders, employees) is junior in payouts.
Liquidation preference (liq pref): Investor gets paid back first — often 1x invested capital — before common receives any proceeds in an exit.
Participating preferred: Investor gets their preference and then shares in remaining proceeds. Less common in top-tier biotech VC but can appear in tougher markets.
Anti-dilution (broad-based weighted average): Protects investors if a future round prices below the current round (a "down round"). Weighted-average is the more standard, less punitive form.
Pay-to-play: Requires existing investors to participate in a financing to keep certain rights or avoid penalties. Usually appears in stressed situations.
Pro-rata rights: Right to maintain ownership percentage by investing in future rounds. Valuable when a company breaks out and rounds are oversubscribed.
Tranched financing: Investment released in stages based on milestones — IND filing, Phase 1 data, etc. Lowers risk for investors; can constrain company flexibility.
Syndicate: Group of investors in a round. The lead investor sets terms; followers join on the same terms.
Board seat / observer: A board seat is voting governance; an observer attends but typically does not vote. Usually tied to ownership threshold or round leadership.

Deal announcement language (how to read it)

"Up to" / total potential value: Headline value including all milestones. Actual cash paid depends on clinical, regulatory, and commercial success.
Upfront: Guaranteed payment at signing or close. The most useful number for comparing deals — everything else is contingent.
Milestones: Contingent payments tied to specific development, regulatory, or commercial outcomes.
Royalties: Percentage of net sales paid to a licensor on an ongoing basis. Common in licensing and asset deals.
Equity value vs enterprise value (EV): Equity value is the value paid for shares. EV adjusts for net debt and sometimes other items. Press releases typically cite equity value.

Public market financing terms

IPO: Initial public offering. Biotech IPOs often price on catalysts and crossover support, and may include insider participation at the offer price.
Follow-on offering: A public company selling new shares after IPO — often after a catalyst or when the equity market window is open.
ATM (at-the-market): Program to sell shares gradually into the open market. Useful for opportunistic fundraising without a single large transaction.
PIPE: Private investment in public equity. Often used when the public market window is weak; can be dilutive and may include warrants or discounts.
Warrants: Option-like securities that let holders buy shares later at a set price. Common in PIPEs, venture debt, and stressed financings.

Biotech M&A terms

Tender offer: The acquirer offers to buy shares directly from shareholders at a set price. The standard mechanism in public company takeouts.
CVR (contingent value right): A right to receive additional payout if specified milestones are met post-acquisition. Used to bridge valuation gaps between buyer and seller.
Earnout: Additional payment based on performance targets post-close. Less common in pure biotech M&A than in services or software deals.
Break fee (termination fee): Fee paid if the deal is terminated under specific conditions — e.g., a superior proposal. The size and direction signal deal certainty dynamics.

Quick FAQs

What's the difference between pre-money and post-money?

Pre-money is the valuation before new investment; post-money is after. Post-money = pre-money + amount raised.

Why do biotech deals use "up to" numbers?

To share risk: the upfront is guaranteed cash at signing, while milestone payments only occur if the science and regulatory process succeed. The headline 'up to' figure is the theoretical maximum.

What is a CVR and why do acquirers use it?

A contingent value right is a post-close payout that activates if specific milestones are hit. It lets a buyer pay less upfront while giving sellers upside participation if key events — Phase 3 data, FDA approval, sales thresholds — come through.